WASHINGTON — The lead-up to the drug-eluting stent (DES) guidance published by FDA earlier this year (Medical Device Daily; March 28, 2008) probably triggered at least a fair amount of anxiety among firms working on new DES products, a fact that was not lost on the organizers of the 2008 edition of Transcatheter Cardiovascular Therapeutics (TCT 2008). One of the sessions held Wednesday, deemed a hot topic, was titled, "New DES Guidance: Does Preserving Safety Blunt Innovation?" (Medical Device Daily)